Guest Editor's Memo

Advances in Pulmonary Hypertension

关键词: WHO Group 1- Pulmonary Arterial Hypertension;    Support;    Genetics;    Genetic Testing;    Endoglin;    HHT (hereditary hemorrhagic telangiectasia);    systemic disorders;    nitric oxide;    endothelial dysfunction;    Medical Membership Network;    CME;    Classification;   

DOI  :  

学科分类：医学（综合）

来源: Pulmonary Hypertension Association

【 摘 要 】

The physiological, cardiovascular, and pulmonary changes that occur during pregnancy have been associated with high maternal mortality in PAH, and thus pregnancy avoidance and use of adequate contraception are important.12,13 Additionally, one of the most common categories of medications to treat PAH, the endothelin receptor antagonists (ERAs), are category X in pregnancy, as they caused severe birth defects in animal studies.14 Pregnancy must be excluded prior to initiating therapy and women must be educated about the risks, required monthly pregnancy testing, and need for adequate contraception (Table 2; see also Pregnancy article and Contraception in PH article for additional details).15,16 Women should be advised to notify their health care professional of any delay in onset of menses or any other reason to suspect pregnancy, so that immediate pregnancy testing can be performed and the ERA discontinued.

【 授权许可】

All Rights reserved